Axsome Therapeutics
Stock Forecast, Prediction & Price Target
Axsome Therapeutics (AXSM) stock Price Target by analysts
$135
Potential upside: 20.53%
Axsome Therapeutics price prediction
What is Axsome Therapeutics stock analysts` prediction?
Axsome Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Axsome Therapeutics in the last 3 months, the avarage price target is $135, with a high forecast of $NaN. The average price target represents a 20.53% change from the last price of $112.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Axsome Therapeutics stock Price Target by analysts
Full breakdown of analysts given Axsome Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Yatin Suneja Guggenheim | 0% 0/1 | 11 months ago | $135 20.53% upside | $99.49 | StreetInsider | Previous targets (0) |
Graig Suvannavejh Mizuho Securities | 0% 0/2 | about 1 year ago | $106 -5.35% downside | $90.58 | StreetInsider | Previous targets (1) |
Cerena Chen Wells Fargo | 0% 0/1 | about 1 year ago | $140 25% upside | $88.86 | TheFly | Previous targets (0) |
Jason Gerberry Bank of America Securities | 0% 0/1 | about 1 year ago | $106 -5.35% downside | $83.93 | StreetInsider | Previous targets (0) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | about 1 year ago | $180 60.71% upside | $83.21 | TheFly | Previous targets (0) |
Leonid Timashev RBC Capital | 0% 0/2 | about 1 year ago | $131 16.96% upside | $84.85 | StreetInsider | Previous targets (1) |
Leonid Timashev RBC Capital | 0% 0/2 | over 1 year ago | $130 16.07% upside | $72.24 | StreetInsider | Previous targets (1) |
David Amsellem Piper Sandler | 0% 0/1 | over 1 year ago | $115 2.67% upside | $75.19 | StreetInsider | Previous targets (0) |
Vikram Purohit Morgan Stanley | 0% 0/1 | over 1 year ago | $115 2.67% upside | $74.14 | StreetInsider | Previous targets (0) |
Graig Suvannavejh Mizuho Securities | 0% 0/2 | over 1 year ago | $109 -2.67% downside | $79.17 | StreetInsider | Previous targets (1) |
Joel Beatty Robert W. Baird | 0% 0/1 | over 1 year ago | $108 -3.57% downside | $72.54 | StreetInsider | Previous targets (0) |
Unknown Piper Sandler | N/A | over 2 years ago | $75 -33.03% downside | $73.34 | Benzinga | N/A |
Robert Hazlett BTIG | 0% 0/1 | almost 3 years ago | $98 -12.5% downside | $75.13 | TheFly | Previous targets (0) |
Unknown Morgan Stanley | N/A | almost 3 years ago | $86 -23.21% downside | $74.95 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $85 -24.10% downside | $74.74 | Benzinga | N/A |
Unknown Guggenheim | N/A | almost 3 years ago | $80 -28.57% downside | $55.49 | Benzinga | N/A |
Joon Lee Truist Financial | 0% 0/2 | about 3 years ago | $150 33.92% upside | $59.03 | TheFly | Previous targets (1) |
Unknown Mizuho Securities | N/A | over 3 years ago | $49 -56.25% downside | $34.04 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 3 years ago | $27 -75.89% downside | $30.59 | Benzinga | N/A |
Joon Lee Truist Financial | 0% 0/2 | over 3 years ago | $90 -19.64% downside | $30.98 | Pulse 2.0 | Previous targets (1) |
Ashwani Verma Bank of America Securities | 100% 1/1 | about 4 years ago | $25 -77.67% downside | $23.78 | StreetInsider | Previous targets (0) |
Axsome Therapeutics Financial Estimates
Axsome Therapeutics Revenue Estimates
Axsome Therapeutics EBITDA Estimates
Axsome Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $50.03M 0% | $270.6M 440.79% | Avg: $671.48M Low: $493.50M High: $778.84M avg. 148.14% | Avg: $1.11B Low: $888.85M High: $1.33B avg. 66.17% | Avg: $1.56B Low: $1.24B High: $1.86B avg. 40.04% | Avg: $2.04B Low: $1.62B High: $2.43B avg. 30.55% |
Net Income
% change YoY
| $-134.94M N/A | $-197.76M -46.55% | $-239.23M -20.96% | Avg: $-16.45M Low: $-180.79M High: $154.44M avg. 93.12% | Avg: $323.72M Low: $8.63M High: $626.86M avg. 2067.37% | Avg: $556.58M Low: $409.38M High: $696.33M avg. 71.93% | Avg: $758.34M Low: $557.77M High: $948.73M avg. 36.24% |
EBITDA
% change YoY
| $-124.70M N/A | $-170.93M -37.07% | $-224.99M -31.62% | Avg: $181.21M Low: $133.17M High: $210.18M avg. 180.54% | Avg: $301.13M Low: $239.86M High: $359.29M avg. 66.17% | Avg: $421.72M Low: $335.92M High: $503.17M avg. 40.04% | Avg: $550.60M Low: $438.58M High: $656.93M avg. 30.55% |
EPS
% change YoY
| -$3.59 N/A | -$4.86 -35.37% | -$5.27 -8.43% | Avg: -$0.23 Low: -$3.98 High: $3.4 avg. 95.71% | Avg: $6.4 Low: $0.19 High: $13.8 avg. 2933.81% | Avg: $12.25 Low: $9.01 High: $15.33 avg. 91.46% | Avg: $16.69 Low: $12.28 High: $20.89 avg. 36.24% |
Operating Expenses
% change YoY
| $124.70M N/A | $221.34M 77.48% | $476.36M 115.21% | Avg: $990.68M Low: $728.09M High: $1.14B avg. 107.96% | Avg: $1.64B Low: $1.31B High: $1.96B avg. 66.17% | Avg: $2.30B Low: $1.83B High: $2.75B avg. 40.04% | Avg: $3.01B Low: $2.39B High: $3.59B avg. 30.55% |
FAQ
What is Axsome Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 567.16% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is -180.79M, average is -16.45M and high is 154.44M.
What is Axsome Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 71.23% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $493.50M, average is $671.48M and high is $778.84M.
What is Axsome Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 789.30% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is -$3.98, average is -$0.23 and high is $3.4.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Axsome Therapeutics stock. The most successful analyst is Yatin Suneja.